Acelyrin

Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.

ABBV

ALMS

CORT

DBVT

SLRN


With tariffs sending markets reeling in the first days of the second quarter—the S&amp;P 500 dropped roughly 10% in the five trading periods through Apr. 7, 2025—investors with cash to spend might be looking

3 Biopharmaceutical Stocks Bucking the Sell-Off

Konskie,,Poland,-,December,03,,2024:,Rpm,International,Company,Logo

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AMST

CTAS

GETY

HOTH

LFWD

SSTK

Nasdaq Down 1.5%; RPM Posts Upbeat Results

Wall Street

LIDR

XTIA

Dow Surges Over 100 Points; US Trade Deficit Widens In November

Acelyrin Inc

Press Releases

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDW, BHLB, MHLD, SLRN on Behalf of Shareholders

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating The Merger - SLRN, TURN, BHLB, MHLD

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, BECN, SLRN, ALMS on Behalf of Shareholders

Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - OPTN, SLRN, AKYA, SHYF

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, SLRN, AKYA, SHYF on Behalf of Shareholders

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, SLRN, BECN on Behalf of Shareholders

Alumis and ACELYRIN Announce Amended Merger Agreement

AKYA

AMPS

BECN

BHLB

BRDG

MHLD

OPTN

SHYF

TURN

Anika Therapeutics

Annexon

Candel Therapeutics

Cardiff Oncology

Cargo Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Design Therapeutics

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

Foghorn Therapeutics

Gossamer Bio

Humacyte

Immutep Limited - American Depositary Shares

Immutep

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Inventiva S.A. - American Depository Shares

Inventiva

Kodiak Sciences

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Monopar Therapeutics

Neurogene

Nuvectis Pharma

Ocugen

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

Prime Medicine

Regulus Therapeutics

Voyager Therapeutics, Inc. - Common Stock

Voyager Therapeutics

Y-mAbs Therapeutics

Citigroup

HC Wainwright & Co.

Wells Fargo

Morgan Stanley

Piper Sandler

Comments

Acelyrin

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell